Clin2
NCT06520540Likely a fitNot yet recruiting

HDM1002 tablets for weight loss in Chinese adults

Glucagon-Like Peptide-1 Receptor Agonists

Treatments studied

Part of Hormones & metabolism clinical trials.

This trial tests an experimental tablet called HDM1002 for weight loss in Chinese adults who are overweight or obese. It aims to see if the medication is safe and helps with weight management.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
72 people
Ages
18 years to 60 years
Study type
Interventional

Who can take part

  • You are between 18 and 60 years old.
  • Your BMI (body mass index) is between 24 and 36.
  • You agree to use effective birth control if you could become pregnant or get someone pregnant.
  • You have not gained or lost more than 5% of your body weight in the past 3 months.
  • You do not have a history of diabetes or serious health problems like heart disease or pancreatitis.
  • You have not used weight-loss drugs in the last 3 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07279194Recruiting· Phase 3
Study of HDM1005 for weight loss in Chinese adults without diabetes

This trial tests a new medication, HDM1005, to help people with obesity or overweight who do not have diabetes lose weight. It is for Chinese adults who have a high body mass index (BMI) or a BMI above 24 with weight-related health problems like high blood pressure or fatty liver.

Shanghai
NCT06576401Recruiting· Phase 1
HDM1002 metabolism study in healthy Chinese men

This study tests how a new drug called HDM1002 leaves the body, using a tiny amount of a radioactive marker. It's for healthy men, and the results will help researchers understand how the drug works.

Suzhou, Jiangsu
NCT06608329Not yet recruiting· Phase 1
Study of HDM1002: How it works with and without food

This study looks at how the drug HDM1002 is absorbed by the body, both when taken with food and on an empty stomach. It helps researchers understand the best way to take the medication.

Hangzhou, Zhejiang
NCT06985615Recruiting· Phase 1
Study of HDM1002 in people with and without liver problems

This trial tests a medicine called HDM1002 in people who have different levels of liver function. It aims to see how the liver affects the drug and if it is safe.

Suzhou, Jiangsu
NCT07521631Recruiting· Phase 2
HDM1005 versus Tirzepatide for weight management in obese adults

This study tests whether a new injectable medication called HDM1005 works as well as tirzepatide (a GLP-1 drug) for weight loss in adults with obesity but no diabetes. Both medications work similarly in the body to help control appetite and weight.

Shanghai
NCT06885021Not yet recruiting· Phase 3
Study of HDM1002 for weight loss in overweight and obese adults

This trial tests a new medication, HDM1002, to help people with excess weight lose weight and keep it off. You may qualify if you have a high BMI or a lower BMI with weight-related health problems, and you have struggled to lose weight through diet and exercise alone.

Hear when a new Glucagon-Like Peptide-1 Receptor Agonists trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.